Risk Stratification for Cardiovascular Disease Based on Prior Coronary Artery Disease, Cerebrovascular Disease and Diabetes Mellitus

Author:

Oe Momoko1,Fujihara Kazuya1,Yamada Mayuko Harada1,Osawa Taeko1,Kitazawa Masaru1,Matsubayashi Yasuhiro1,Sato Takaaki1,Yaguchi Yuta1,Iwanaga Midori1,Yamada Takaho1,Sone Hirohito1

Affiliation:

1. Niigata University Faculty of Medicine

Abstract

Abstract Background: Although the impact of a history of coronary artery disease (CAD), cerebrovascular disease (CVD) or both and diabetes mellites (DM) on cardiovascular disease is essential for cardiovascular risk management in clinical practice, little is known about such an impact. Therefore, we investigated the association of prior CAD, prior CVD, DM and their combinations with the risk of subsequent cardiovascular disease. Methods: This historical cohort study included 342,033 participants aged 18-72 years followed for ≥5 years between 2008-2016. Eight groups were created according to whether they were with or without prior CAD, prior CVD and/or DM. DM was defined by fasting plasma glucose, HbA1c and antidiabetic drug prescription. Prior and subsequent CAD and CVD were identified by claims using ICD-10 codes, medical procedures and questionnaires. Cox regression models evaluated the risk of cardiovascular events. Results: Median follow-up period was 6.4 years. Incidence of composite cardiovascular events due to CAD and/or CVD in CAD-/CVD-, CAD+/CVD-, CAD-/CVD+ and CAD+/CVD+ groups were 1.92, 6.94, 25.14 and 31.98 per 1,000 person-years in non-DM and 8.66, 18.04, 39.98 and 60.72 in DM, respectively. Hazard ratio of cardiovascular events compared to CAD-/CVD-/non-DM were 1.66 (95% CI 1.55-1.78) in CAD-/CVD-/DM and 1.84 (1.56-2.18) in CAD+/CVD-/non-DM. CVD+ increased the risk of cardiovascular events approximately 4- to 7- fold regardless of CAD+ or DM. Conclusions:DM increase the risk of cardiovascular disease as high as a history of CAD, while prior CVD alone increased the risk of future cardiovascular disease without additional effects by DM.

Publisher

Research Square Platform LLC

Reference35 articles.

1. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice;Visseren FLJ;Eur Heart J,2021

2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 139(25):e1082-e1143.

3. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association;Kleindorfer DO;Stroke,2021

4. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent C;Lancet,2010

5. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry;Sorbets E;Eur Heart J,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3